PDS5B

Across TCGA pan-cancer cohorts, PDS5B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PDS5B data layer compared with 29 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PDS5B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PDS5B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, LIHC, and BRCA are the cancer types where PDS5B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.259	0.542	.004	30	view →
LIHC	OS	Median	II,III,IV	0.051	0.772	<.001	21	view →
BRCA	DFS	Median	III,IV	0.201	0.796	.001	14	view →
UCEC	OS	Median	II,III,IV	0.894	0.317	.017	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PDS5B–OV (DFS)

Open the OV breakdown →